Banking, capital & valuation

Yes, but incrementally — and the access is conditioned on being registered.

Several institutions have signaled they'll treat DEA registration as the threshold for opening cannabis-banking relationships under the new regime. A registered medical operator is a meaningfully different banking customer than an unregistered one, even if both hold the same OMMA license.

Expect a tiered market over the next 12 to 18 months. Registered medical-only operators see real improvement in account access, payment relationships, and depository services. Mixed operators — medical plus recreational — face slower progress because the recreational exposure remains Schedule I. Recreational-only operators see little change in 2026.

For an OMMA-licensed medical operator, the path to better banking runs through the DEA registration.

Yes. The rescheduling solved part of the banking problem — for state-licensed medical operators. SAFE Banking would solve the rest of it, particularly for recreational and rec-exposed operators.

The political case for SAFE Banking is now more complicated. Some legislators will argue the rescheduling reduces the urgency. Others will argue that registered medical operators now have a clearer story to tell about why SAFE is still needed for the parts of the industry the rescheduling didn't reach.

For OMMA-licensed medical operators specifically, SAFE's incremental value is smaller than it was before April 28. The rescheduling did the heavy lifting. SAFE would be additive rather than transformative.

On a similar trajectory to banking, with a delay.

Major processors — Visa, Mastercard, Stripe, Square — haven't announced blanket policy changes. But specialized cannabis-payments providers are repositioning around DEA-registered medical as a distinct category they'll work with on better terms than general cannabis-sector activity.

ACH and depository changes through the banking channel will likely lead card-network changes by months. So depository access improves first; merchant card acceptance improves later.

For OMMA-licensed dispensaries operating mostly on cash and limited debit programs, the improvement is real but will be gradual through 2026 and into 2027.

Materially positive across all three dimensions for medical-positioned operators.

Valuation. 280E reversal flows directly to free cash flow, which is the input that drives most cannabis-sector valuations. Multiples should expand as the sector normalizes toward standard consumer or health-product comparables, rather than carrying the depressed cannabis-discount that 280E created.

Debt capacity. Improved free cash flow improves debt-service coverage, which is what lenders look at. Operators who couldn't carry traditional debt under 280E can now carry materially more.

M&A activity. Expect acceleration. Balance sheets are unlocking, acquirer financing is improving, and the regulatory environment is moving toward something resembling a normal industry rather than a quasi-illegal one. Strategic and financial buyers that had been on the sidelines are reentering.

For Oklahoma operators specifically, this matters most for owners contemplating an exit or a recapitalization. The window for transacting at improved multiples is opening.

Improving for medical-focused operators, with caveats.

U.S. major-exchange listing — NYSE, NASDAQ — has been gated by Schedule I status. That gate opens, partially, for operators whose business is meaningfully Schedule III. The path isn't fully clear yet; the exchanges and their regulators are working through what compliance looks like for registered medical operators.

Mixed operators with recreational exposure face the harder path. The Schedule I residual on the recreational side creates ongoing listing complications that medical-only operators won't face.

Canadian-listed U.S. MSOs are evaluating uplisting to U.S. major exchanges. The decision is entity-by-entity and depends on operating mix, regulatory posture, and timing relative to broader regulatory clarity.

For private capital — non-public raises — the environment is improving across the board. More institutional capital, better terms, less regulatory friction.

Cannabis-sector insurance markets have been thin and expensive — small numbers of carriers, high pricing, narrow coverage. Early signals suggest meaningful softening for registered medical operators.

Expect improvement across the main lines: general liability, product liability, property, and directors-and-officers (D&O) for operators with institutional ownership.

The timeline for pricing to normalize is 6 to 18 months. The insurers that lead the cannabis market need time to gather loss experience under the new regime, update their underwriting frameworks, and adjust pricing. Operators should expect modest improvement in 2026 with more substantial improvement in 2027 renewals.

Yes, in several ways.

Forward cash flow. 280E savings starting in tax year 2026 improve EBITDA-to-cash conversion immediately. That changes the look of the business to lenders and investors who price on cash-flow metrics.

Deferred tax assets. Under 280E, future deductions were largely presumed disallowed. With deductions presumed allowable going forward, deferred tax asset positions shift. Your auditors will need to revalue these positions for 2026.

Retroactive refunds. If Treasury eventually issues retroactive 280E relief (still speculative as of May 2026 — see the 280E section), refund-anticipation financing becomes viable for prior tax years. Some specialty lenders are positioning for this market already; it isn't available yet.

Lender treatment. Lenders that price on EBITDA or free cash flow will see immediate improvement in your numbers under the new regime. That feeds into both new financings and renewals of existing facilities.

Engage your auditors early. The first reporting period under the new regime will set disclosure norms for the sector.

The main mechanical changes:

Tax expense. Drops materially starting Q2 2026 — effectively from April 28 forward. Quarterly reporting from Q2 2026 onward will reflect substantially different tax expense than prior periods.

Effective tax rate. ETR disclosure should reflect the rescheduling. Prior-period comparability requires narrative disclosure explaining why the rates moved.

Deferred tax assets and liabilities. Revaluation required given that future deductibility is now presumed rather than presumed-disallowed.

Prior-period comparability. Side-by-side reporting needs narrative context. Investors and lenders looking at multi-year trends need to understand that the comparison points are not on the same regulatory basis.

Retroactive relief. If and when it lands, will trigger additional restatement work for prior years.

This is auditor and CPA territory. Get them engaged on the Q2 2026 close, not the year-end close.